News Column

Study Findings from E. Lopez-Gordo et al Broaden Understanding of Gene Therapy

May 29, 2014



By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Investigators discuss new findings in Biotechnology. According to news originating from Barcelona, Spain, by NewsRx correspondents, research stated, "Adenoviruses are efficient gene delivery vectors based on their ability to transduce a wide variety of cell types and drive high-level transient transgene expression. While there have been advances in modifying human adenoviral (HAdV) vectors to increase their safety profile, there are still pitfalls that need to be further addressed."

Our news journalists obtained a quote from the research, "Preexisting humoral and cellular immunity against common HAdV serotypes limits the efficacy of gene transfer and duration of transgene expression. As an alternative, nonhuman AdV (NHAdV) vectors can circumvent neutralizing antibodies against HAdVs in immunized mice and monkeys and in human sera, suggesting that NHAdV vectors could circumvent preexisting humoral immunity against HAdVs in a clinical setting. Consequently, there has been an increased interest in developing NHAdV vectors for gene delivery in humans."

According to the news editors, the research concluded: "In this review, we outline the recent advances and limitations of HAdV vectors for gene therapy and describe examples of NHAdV vectors focusing on their immunogenicity, tropism, and potential as effective gene therapy vehicles."

For more information on this research see: Circumventing Antivector Immunity: Potential Use of Nonhuman Adenoviral Vectors. Human Gene Therapy, 2014;25(4):285-300. Human Gene Therapy can be contacted at: Mary Ann Liebert, Inc, 140 Huguenot Street, 3RD Fl, New Rochelle, NY 10801, USA. (Mary Ann Liebert, Inc. - www.liebertpub.com; Human Gene Therapy - www.liebertpub.com/overview/human-gene-therapy-and-part-b-methods/19/)

The news correspondents report that additional information may be obtained from E. Lopez-Gordo, Inst Invest Biomed Bellvitge, Inst Catala Oncol, Lab Recerca Translac, Barcelona 08907, Spain. Additional authors for this research include I.I. Podgorski, N. Downes and R. Alemany (see also Biotechnology).

Keywords for this news article include: Biotechnology, Spain, Europe, Therapy, Barcelona

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Gene Therapy Weekly


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters